The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Open accessAbstract
Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the sample cohort. High‐grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred to as high‐grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC, we sequenced exons 2–11 and intron–exon boundaries in tumour DNA from 145 patients. HGPSC cases were defined as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were identified in 96.7% ( n = 119/123) of HGPSC cases. Molecular and pathological review of mutation‐negative cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4 , or indicated the exclusion of samples as being low‐grade serous tumours or carcinoma of uncertain primary site. Overall, p53 dysfunction rate approached 100% of confirmed HGPSCs. No association between TP53 mutation and progression‐free or overall survival was found. From this first comprehensive mapping of TP53 mutation rate in a homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic or predictive significance. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer3 on the WWW for General Users and for Biologist Programmers
Rozen, S., & Skaletsky, H. (2003) · Bioinformatics Methods and Protocols · doi:10.1385/1-59259-192-2:365 · Cited by 15,013
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
The ubiquitin ligase COP1 is a critical negative regulator of p53
Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., O' Rourke, K., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 704
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier, M., Langer√∏d, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., Theillet, C., Rodriguez, C., Lidereau, R., Bi√®che, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1029 · Cited by 589
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
The distal fallopian tube: a new model for pelvic serous carcinogenesis
Crum, C. P., Drapkin, R., Miron, A., Ince, T. A., Muto, M., Kindelberger, D. W., & Lee, Y. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011a21f · Cited by 512
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke‐Pearson, D. L., Iglehart, J. D., Bast, R. C., & Berchuck, A. (1991) · PubMed · Cited by 465
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Rustin, G. J. S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., et al. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh081 · Cited by 378
Zorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Etemadmoghadam, D., deFazio, A., Beroukhim, R., Mermel, C., George, J., Getz, G., Tothill, R., Okamoto, A., Raeder, M. B., AOCS Study Group, et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1564 · Cited by 302
Self-citationp53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk, J., Thor, A. D., Beauchamp, R., Merritt, V, Edgerton, S. M., Bell, D. A., & Yandell, D. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4961 · Cited by 289
Shimizu, Y., Kamoi, S., Amada, S., Akiyama, F., & Silverberg, S. G. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<893::aid-cncr14>3.0.co;2-w · Cited by 254
Riemenschneider, M. J., Büschges, R., Wolter, M., REIFENBERGER, J., Boström, J. P., Kraus, J. A., Schlegel, U. S., & Reifenberger, G. (1999) · PubMed · Cited by 247
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors [Ovarian Cancer]
Vergote, I. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1534 · Cited by 239
Wang, T.-L., Maierhofer, C., Speicher, M. R., Lengauer, C., Vogelstein, B., Kinzler, K. W., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202610899 · Cited by 219
Meinhold-Heerlein, I., Bauerschlag, D., Hilpert, F., Dimitrov, P., Sapinoso, L. M., Orlowska-Volk, M., Bauknecht, T., Park, T.-W., Jonat, W., Jacobsen, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208298 · Cited by 205
Frequent allelic losses and mutations of the p53 gene in human ovarian cancer.
Okamoto, A., Sameshima, Y., Yokoyama, S., Terashima, Y., Sügimura, T., Terada, M., & Yokota, J. (1991) · PubMed · Cited by 189
High Incidence of Protein-Truncating TP53 Mutations in BRCA1-Related Breast Cancer
Holstege, H., Joosse, S. A., van Oostrom, C. T. M., Nederlof, P. M., de Vries, A., & Jonkers, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3426 · Cited by 171
Recent advances in p53 research: an interdisciplinary perspective
Olivier, M., Petitjean, A., Marcel, V, Pétré, A., Mounawar, M., Plymoth, A., de Fromentel, C. C., & Hainaut, P. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2008.69 · Cited by 161
Dehari, R., Kurman, R. J., Logani, S., & Shih, I. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31802cbbe9 · Cited by 150
Locus-specific mutation databases: pitfalls and good practice based on the p53 experience
Soussi, T., Ishioka, C., Claustres, M., & Béroud, C. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1783 · Cited by 144
Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
Similar outcome of elderly patients in Intergroup Trial 0096
Yuen, A. R., Zou, G., Turrisi, A. T., Sause, W. T., Komaki, R. R., Wagner, H., Aisner, S. C., Livingston, R. B., Blum, R. H., & Johnson, D. H. (2000) · Cancer · doi:10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7 · Cited by 140
Estimation and assessment of raw copy numbers at the single locus level
Bengtsson, H. L., Irizarry, R. A., Carvalho, B. S., & Speed, T. P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn016 · Cited by 139
McCann, A. H., Kirley, A., Carney, D. N., Corbally, N., Magee, H. M., Keating, G., & Dervan, P. A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.189 · Cited by 125
Salani, R., Kurman, R. J., Giuntoli, R. L., Gardner, G. J., Bristow, R. E., Wang, T., & Shih, I. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01039.x · Cited by 120
Jordan, S. J., Green, A. C., Whiteman, D. C., Moore, S., Bain, C. J., Gertig, D. M., Webb, P. M., & Chenevix‐Trench, G. (2007) · International Journal of Cancer · doi:10.1002/ijc.23287 · Cited by 114
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips, K., Nichol, K., Ozçelik, H., Knight, J., Done, S., Goodwin, P., & Andrulis, I. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.469 · Cited by 111
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
de Graeff, P., Crijns, A. P. G., de Jong, S., Boezen, M., Post, W. J., de Vries, E. G. E., van der Zee, A. G. J., & de Bock, G. H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605112 · Cited by 108
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations
Li, Y., Guessous, F., Kwon, S., Kumar, M., Ibidapo, O., Fuller, L., Johnson, E., Lal, B., Hussaini, I., Bao, Y., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1963 · Cited by 95
Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival
Bartel, F., Jung, J., Böhnke, A., Gradhand, E., Zeng, K., Thomssen, C., & Hauptmann, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1192 · Cited by 67
Critical evaluation of p53 as a prognostic marker in ovarian cancer
Hall, J. A., Paul, J., & Brown, R. E. (2004) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399404007781 · Cited by 54
Darcy, K. M., Brady, W. E., McBroom, J. W., Bell, J. G., Young, R. C., McGuire, W. P., Linnoila, R. I., Hendricks, D. T., Bonome, T., & Farley, J. H. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.020 · Cited by 47
the Polish Ovarian Cancer Study Group (POCSG), Kupryjańczyk, J., Kraszewska, E., Ziółkowska-Seta, I., Mądry, R., Timorek, A., Markowska, J., STELMACHÓW, J., & Bidziński, M. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-27 · Cited by 30
Høgdall, E. V. S., Christensen, L. H., Høgdall, C. K., Frederiksen, K., Gayther, S. A., Blaakær, J., Jacobs, I. J., & Kjær, S. K. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.00917.x · Cited by 21
Muscolini, M., Montagni, E., Caristi, S., Nomura, T., Kamada, R., Agostino, S. D., Corazzari, M., Piacentini, M., Blandino, G., Costanzo, A., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9910 · Cited by 16
Cited by
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Self-citationRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationMatulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
MuSiC: Identifying mutational significance in cancer genomes
Dees, N. D., Zhang, Q., Kandoth, C., Wendl, M. C., Schierding, W., Koboldt, D. C., Mooney, T. B., Callaway, M. B., Dooling, D., Mardis, E. R., et al. (2012) · Genome Research · doi:10.1101/gr.134635.111 · Cited by 677
Metadata
- Authors
- Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., Bowtell, D., & Brenton, J. D.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2010-04
- Volume
- 221
- Issue
- 1
- Pages
- 49-56
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2089477889
- Cited by
- 787
- References
- 49
- FWCI
- 48.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
